gantenerumab

August 3, 2018August 3, 2018

Genentech Presents Positive Data from Trials on Crenezumab and Gantenerumab for Alzheimer’s

News

The latest clinical data from Genentech on crenezumab and gantenerumab demonstrate the investigational therapies’ potential to reduce amyloid aggregates in Alzheimer’s disease patients. Trial results were discussed in several ... Read more

March 20, 2018March 20, 2018

Phase 3 Trials of Gantenerumab Likely to Decide Clinical Benefit, Roche Says in Interview

News

Roche soon will start two Phase 3 trials testing gantenerumab, its amyloid-targeting treatment candidate, in prodromal, or early, Alzheimer’s patients. Each plans to enroll 750 people, ages 50 to 90, and ... Read more

March 12, 2018March 12, 2018

Roche Set to Start Two Phase 3 Trials of Gantenerumab in People with Early to Mild Alzheimer’s

News

The safety and efficacy of Roche’s gantenerumab, a treatment candidate for Alzheimer’s, will be tested in two global Phase 3 clinical trials in patients with early to mild forms of the disease. ... Read more

March 9, 2017

Roche, MorphoSys Plan Experimental Clinical Trials of Gantenerumab for Alzheimer’s

News

Roche and MorphoSys will partner on experimental Phase 3 clinical trials to study the effectiveness and safety of gantenerumab in patients with early to mild Alzheimer’s disease. Roche, a Swiss global healthcare ... Read more

March 21, 2016March 21, 2016

CONy16: New Alzheimer’s Phase 3 Tests of Amyloid-Beta Immunotherapies and an Exclusive Interview with Researcher

News

Two previously failed drug candidates, Eli Lilly’s Solanezumab and Roche’s Gantenerumab, are again under clinical study for Alzheimer’s disease. Both drugs are immunotherapies targeting amyloid-beta in the brain, a target that researchers ... Read more

January 7, 2015February 11, 2016

SCarletRoAD Trial of Gantenerumab in Prodromal Alzheimer’s Discontinued

News

German biotechnology company, MorphoSys, was informed by its partner, Swiss global health-care company, Roche, about their decision to discontinue gantenerumab‘s Phase III SCarletRoAD trial for prodromal Alzheimer’s Disease patients. This decision is supported by a recommendation from ... Read more

Pin It on Pinterest